KHPG(SZ:002773)2022-12-04 08:58Group 1: Product Sales and Market Expansion - The company is focusing on extensive training for doctors and patients to enhance the sales of Conbercept eye injection, aiming to explore untapped markets [4] - The overseas commercialization of Conbercept is a significant priority, with ongoing global multi-center clinical trials expected to reveal its market value [4] - The global multi-center clinical trial for Conbercept involves over 300 research centers across more than 30 countries, with plans to enroll over 2,000 participants, and the enrollment is already over half complete [4] Group 2: Competitive Advantages and Regulatory Preparedness - Conbercept has been recognized by the WHO with the international non-proprietary name "Conbercept," and it has received FDA approval to skip Phase I and II trials, directly proceeding to Phase III, indicating its technical and safety recognition [5] - The company is preparing for the upcoming national medical insurance negotiations by showcasing the advantages of Conbercept and its contributions [6] Group 3: Research and Development Capabilities - The company has established several innovative platforms, including a national recognized technical center and a postdoctoral research station, to enhance its drug development capabilities [6] - Focus areas for R&D include large molecule protein drug technology, standardized quality control for traditional Chinese medicine, green synthesis of chemical raw materials, and new formulations for solid oral drugs [6] - The company has structured its R&D into three main segments: new drug research, product technology center, and medical research center, integrating domestic and international resources for a comprehensive innovation team [6]